Effects of V.II-BE on the number of circulating virus particles and immune cells in the blood in patients diagnosed positive with HIV

ISRCTN ISRCTN83581730
DOI https://doi.org/10.1186/ISRCTN83581730
Secondary identifying numbers GHS-0312/kl
Submission date
27/09/2012
Registration date
08/10/2012
Last edited
06/06/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
We were carrying out this study in order to measure the effect of an herbal
preparation containing a special extract of the medicinal plants chamomile, rose, lavender,
myrrh, willow bark and spiny rush on HIV infection. The aim is to
test the potential of the herbal preparation for an improvement in virus load and immune cells
in patients diagnosed as HIV positive but not yet eligible for treatment with antiviral
medications. This situation, where the patient cannot receive medication because the risk of
adverse effects and formation of resistance, can be considered a therapeutic gap, leaving the
patient on his/her own with a dreadful perspective. A well-tolerated herbal preparation contributing
to controlling the virus load and the immune status in the early stages of an HIV infection is
expected to increase the quality of life of the patients, and delay the aggravation of the
response of the immune system even to minor threats.

Who can participate?
Adults up to the age of 50 diagnosed with HIV who have a virus load and CD4-cell count below
the threshold for the prescription of an antiviral medical treatment.

What does the study involve?
Within the study, only routine examination results are documented, as they would have been
obtained from regular medical supervision. In addition, the typical laboratory blood
examinations on liver and kidney function and blood lipids are documented as an additional
safety aspect. The study is designed for an observation period of 3 months.

What are the possible benefits and risks of participating?
A delay of the requirement of antiviral treatment is a major clinical achievement in HIV
treatment: it increases the quality of life of HIV patients, and postpones the risk of resistance
formation against antiviral medications, as well as the risk of adverse effects. In previous examinations and experience with exposure to the herbal preparation, no adverse reactions have been observed. Participating patients are screened for potential adverse events.

Where is the study run from?
The study is run from clinical HIV healthcare centres.

When is the study starting and how long is it expected to run for?
The study started in 2012 and is expected to finish in the same year.

Who is funding the study?
Funding has been provided by GHS AG in Liechtenstein, a company financially supporting the
development of the herbal preparation by its inventor, Mrs Monica Volkmar.

Who is the main contact?
Dr Mathias Schmidt
schmidt@herbresearch.de

Contact information

Dr Martin Imhof
Scientific

Dorotheergasse 7
Wien
1010
Austria

Phone +43 1 5130607
Email ordination@imhof.at

Study information

Study designOpen prospective study
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Hospital
Study typeScreening
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleDocumentation of the clinical effect and safety of V.II-BE on immunological parameters of HIV-infected patients: an open prospective trial
Study objectivesThe intake of the herbal preparation V.II-BE contributes to lowering the virus load and increases the number of circulating CD4 cells in patients infected with human immunodeficiency virus (HIV), but still not sufficiently diseased to be eligible for treatment with antiviral medication.
Ethics approval(s)Ethics Committee of the study centre in Cluj, Romania, 28/05/2012
Health condition(s) or problem(s) studiedHIV at a stage where antiviral treatment is not yet recommended according to medical guidelines
InterventionAll patients receive the V.II-BE solution (special extract of the medicinal plants chamomile, rose, lavender, myrrh, willow bark and spiny rush). The product contains 90% ethanol. The recommended dose is 60 drops twice daily with a little water for 3 months.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)V.II-BE (herbal preparation)
Primary outcome measureVirus load and CD4 cell count
Secondary outcome measuresSafety laboratory values
Overall study start date01/06/2012
Completion date31/12/2012

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants30-40
Key inclusion criteria1. Patients up to the age of 50 diagnosed with an HIV infection
2. Virus load below 50,000 copies/ml of blood
3. CD4 cell count above 350 cells/µl of blood
4. Stable virus load for the past 6 months
Key exclusion criteriaPatients cannot be included if:
1. They receive antiviral medication
2. They are treated with antibiotics
3. They undergo chemotherapy for cancer treatment
4. They have a background of abusing alcohol or illicit drugs
5. They have a co-infection with hepatitis
6. They are, in the case of women, pregnant or lactating
Date of first enrolment01/06/2012
Date of final enrolment31/12/2012

Locations

Countries of recruitment

  • Austria
  • Romania

Study participating centre

Dorotheergasse 7
Wien
1010
Austria

Sponsor information

GHS AG (Liechtenstein)
Industry

Letzanaweg 23
POB 20
Triesen
FL-9495
Liechtenstein

Funders

Funder type

Industry

GHS AG (Liechtenstein)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan